Mackenzie Financial Corp Has $42.47 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Mackenzie Financial Corp increased its position in Regeneron Pharmaceuticals by 21.7%, owning 66,960 shares valued at approximately $42.5 million.
• Several institutional investors significantly boosted their stakes in Regeneron, with Capital International Investors raising its holdings by 41.6% and Price T Rowe Associates increasing by 63.5% in the fourth quarter.
• Regeneron Pharmaceuticals reported a miss in quarterly earnings with an EPS of $8.22 compared to a consensus estimate of $8.83, while also announcing a quarterly dividend of $0.88 per share.

Mackenzie Financial Corp boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,960 shares of the biopharmaceutical company's stock after purchasing an additional 11,928 shares during the quarter. Mackenzie Financial Corp owned 0.06% of Regeneron Pharmaceuticals worth $42,468,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Bellwether Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth $1,076,000. LPL Financial LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. LPL Financial LLC now owns 55,245 shares of the biopharmaceutical company's stock valued at $35,038,000 after buying an additional 755 shares during the period. ARK Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.8% during the first quarter. ARK Investment Management LLC now owns 13,694 shares of the biopharmaceutical company's stock valued at $8,685,000 after acquiring an additional 502 shares during the period. Allium Financial Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $256,000. Finally, Integrated Investment Consultants LLC raised its position in shares of Regeneron Pharmaceuticals by 46.8% during the 1st quarter. Integrated Investment Consultants LLC now owns 894 shares of the biopharmaceutical company's stock valued at $567,000 after acquiring an additional 285 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $13.41 during midday trading on Friday, reaching $558.87. 1,656,418 shares of the company were exchanged, compared to its average volume of 858,977. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The business has a 50-day moving average price of $538.05 and a two-hundred day moving average price of $603.39. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The firm has a market capitalization of $60.34 billion, a price-to-earnings ratio of 14.08, a price-to-earnings-growth ratio of 2.10 and a beta of 0.33.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Analysts Set New Price Targets

Several analysts have commented on REGN shares. Bank of America dropped their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday. Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.